• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Polyrizon Ltd.

    4/23/26 4:25:50 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRZ alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox checkedNoneEntity Type
    0001893645
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Polyrizon Ltd.
    Jurisdiction of Incorporation/Organization
    ISRAEL 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Polyrizon Ltd.
    Street Address 1Street Address 2
     8 HAPNINA STREET
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     RAANANA
     ISRAEL
     
     4321545
     +972-9-3740120 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Izraeli
    Tomer
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Executive Officer and Director



    Last NameFirst NameMiddle Name
    Yosef
    Nir
    Ben
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Financial Officer



    Last NameFirst NameMiddle Name
    Ron
    Eyal
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Science Officer



    Last NameFirst NameMiddle Name
    Turgeman
    Tidhar
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Technology Officer



    Last NameFirst NameMiddle Name
    Itzhaik
    Asaf
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Adler
    Oz
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Sidi
    Liat
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Vinokur
    Yehonatan
    Zalman
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Carmel
    Liron
    Street Address 1Street Address 2
     POLYRIZON LTD. 
     8 HaPnina Street
    CityState/Province/CountryZIP/Postal Code
     Raanana
     ISRAEL
     4321545
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-04-07
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox not checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     Aegis Capital Corp.
     000015007
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    1345 Avenue of the Americas
    27th Floor
    City State/Province/CountryZIP/Postal Code
     New York
     UNITED STATES
     10105
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    3499992
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    3499992
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
    The warrants and shares underlying the warrants, were issued in connection with an offering of (i) 87,777 ordinary shares and warrants to purchase 190,000 ordinary shares in a registered direct offering, and (ii) unregistered warrants to purchase 499,999
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    280000
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
    Aegis Capital Corp. is entitled to a cash placement fee equal to 8.0% of the gross proceeds received in the offering and $75,000 for reasonable legal fees and disbursements for its counsel.
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
    The Company intends to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Polyrizon Ltd./s/ Tomer IzraeliTomer IzraeliChief Executive Officer2026-04-23




    Get the next $PLRZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLRZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLRZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Carmel Liron

    4 - Polyrizon Ltd. (0001893645) (Issuer)

    4/1/26 4:15:12 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Izraeli Tomer

    4 - Polyrizon Ltd. (0001893645) (Issuer)

    4/1/26 4:15:14 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Adler Oz

    4 - Polyrizon Ltd. (0001893645) (Issuer)

    4/1/26 4:15:11 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

    RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor. The Company issued Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately $3.5 million. The transactions closed on April 8, 2026. The transacti

    4/8/26 4:16:00 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement

    RAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $3.5 million. The transactions consisted of the sale of 388,888 Units (or Pre-Funded Uni

    4/7/26 8:00:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Provides 2025 and Recent Highlights

    Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, provided 2025 and recent a business update. "Polyrizon has delivered significant progress across its innovative nasal programs, including key regulatory advancements with the FDA, preparation for potential human clinical trials, and valuable medical collaborations, all powered by a strong cash position and a debt-free balance sheet," said Tomer Izraeli, chief executive officer of Polyrizon. Key Highlights of Polyrizon's Achievements in 2025 and Recent Highlights: As of December 31, 2025, t

    3/26/26 9:23:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    SEC Filings

    View All

    SEC Form D filed by Polyrizon Ltd.

    D - Polyrizon Ltd. (0001893645) (Filer)

    4/23/26 4:25:50 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-1 filed by Polyrizon Ltd.

    F-1 - Polyrizon Ltd. (0001893645) (Filer)

    4/23/26 4:15:52 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    4/8/26 4:16:30 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    Leadership Updates

    Live Leadership Updates

    View All

    Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

    Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

    12/19/24 7:22:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

    Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i

    12/13/24 6:25:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care